Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

07:17
08/19/19
08/19
07:17
08/19/19
07:17

FDA PDUFA Date for Roche Polatuzumab Vedotin is August 19, 2019

  • 19

    Aug

  • 21

    Aug

  • 26

    Aug

  • 02

    Sep

  • 09

    Sep

  • 04

    Nov

RHHBY Roche
$0.00

(0.00%)

07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/23/19
BTIG
07/23/19
INITIATION
Target $46
BTIG
Buy
Adaptive Biotechnologies initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Adaptive Biotechnologies (ADPT) with a Buy rating and a price target of $46, saying the company's "clinical immunomics database" represents its "differentiating asset" and offers "incredible value" to biopharma companies. The analyst further cites Adaptive Biotechnologies' partnership with Roche (RHHBY) that should allow it to develop new diagnostics for early detection of diseases where antigens are unknown and also its "strategic" deal with Microsoft (MSFT), whose machine learning capabilities support its immune medicine platform.
07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.
07/26/19
UBSW
07/26/19
UPGRADE
UBSW
Buy
Roche upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded Roche to Buy from Neutral and raised his price target for the shares to CHF 300 from CHF 270. The company's legacy portfolio, built around Herceptin and Rituxan, is showing greater resilience while its "credible" neuroscience pipeline is taking shape, Leuchten tells investors in a research note. As such, he now sees Roche's business model as less challenged.

TODAY'S FREE FLY STORIES

ONCE

Spark Therapeutics

$104.41

-0.41 (-0.39%)

07:43
09/18/19
09/18
07:43
09/18/19
07:43
Hot Stocks
Spark Therapeutics, paralympic skier partner for genetic testing awareness »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$152.55

1.38 (0.91%)

07:42
09/18/19
09/18
07:42
09/18/19
07:42
Recommendations
KLA-Tencor analyst commentary  »

KLA-Tencor price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$1.73

-0.045 (-2.54%)

07:40
09/18/19
09/18
07:40
09/18/19
07:40
Hot Stocks
vTv Therapeutics presents additional data from Phase 2 Simplici-T1 study »

vTv Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Oct

07:40
09/18/19
09/18
07:40
09/18/19
07:40
General news
Treasury Market Outlook: yields extended declines overnight »

Treasury Market Outlook:…

GSK

GlaxoSmithKline

$41.10

0.49 (1.21%)

07:38
09/18/19
09/18
07:38
09/18/19
07:38
Conference/Events
FDA Non-Prescription Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

OPGN

OpGen

$7.02

-0.07 (-0.99%)

07:37
09/18/19
09/18
07:37
09/18/19
07:37
Hot Stocks
OpGen says Curetis collaborator obtains option to license ARESdb »

OpGen reported an update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$438.98

3.12 (0.72%)

, TROW

T. Rowe Price

$117.98

1.1 (0.94%)

07:37
09/18/19
09/18
07:37
09/18/19
07:37
Recommendations
BlackRock, T. Rowe Price analyst commentary  »

BlackRock's…

BLK

BlackRock

$438.98

3.12 (0.72%)

TROW

T. Rowe Price

$117.98

1.1 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Sep

  • 27

    Oct

AXDX

Accelerate Diagnostics

$21.30

1.85 (9.51%)

07:36
09/18/19
09/18
07:36
09/18/19
07:36
Hot Stocks
Accelerate Diagnostics reports 'positive' results in three Pheno system studies »

Accelerate Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

, WWE

WWE

$75.88

1.73 (2.33%)

07:35
09/18/19
09/18
07:35
09/18/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

ADBE

Adobe

$284.59

1.54 (0.54%)

WWE

WWE

$75.88

1.73 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

BIIB

Biogen

$238.65

2.54 (1.08%)

07:34
09/18/19
09/18
07:34
09/18/19
07:34
Hot Stocks
Biogen to present new data from SHINE study on safety and efficacy of SPINRAZA »

Biogen announced updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

IAC

IAC

$236.73

7.5 (3.27%)

, MTCH

Match Group

$79.70

3 (3.91%)

07:33
09/18/19
09/18
07:33
09/18/19
07:33
Recommendations
IAC, Match Group, Angi Homeservices analyst commentary  »

IAC spinoffs could unlock…

IAC

IAC

$236.73

7.5 (3.27%)

MTCH

Match Group

$79.70

3 (3.91%)

ANGI

Angi Homeservices

$7.60

-0.31 (-3.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

EFX

Equifax

$141.79

1.78 (1.27%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Equifax partners with Urjanet for utility payment data sharing platform »

Equifax and Urjanet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 13

    Nov

BHVN

Biohaven Pharmaceutical

$47.24

-0.8 (-1.67%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Biohaven Pharmaceutical's verdiperstat selected for ALS platform trial »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$238.65

2.54 (1.08%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Biogen to initiate DEVOTE clinical trial evaluating higher dose of SPINRAZA »

Biogen announced updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FDX

FedEx

$173.53

-0.14 (-0.08%)

, UPS

UPS

$122.40

-0.245 (-0.20%)

07:30
09/18/19
09/18
07:30
09/18/19
07:30
Recommendations
FedEx, UPS analyst commentary  »

Hard to see rebound for…

FDX

FedEx

$173.53

-0.14 (-0.08%)

UPS

UPS

$122.40

-0.245 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

MAS

Masco

$41.28

-1.44 (-3.37%)

07:29
09/18/19
09/18
07:29
09/18/19
07:29
Downgrade
Masco rating change  »

Masco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

07:24
09/18/19
09/18
07:24
09/18/19
07:24
Conference/Events
Tandem Diabetes management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Recommendations
Adobe analyst commentary  »

Adobe weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

GLW

Corning

$28.25

-1.79 (-5.96%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Recommendations
Corning analyst commentary  »

Corning shares remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNH

Syneos Health

$54.63

-0.77 (-1.39%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Conference/Events
Syneos Health management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 27

    Sep

AXSM

Axsome Therapeutics

$28.17

-0.97 (-3.33%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Initiation
Axsome Therapeutics initiated  »

William Blair starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

07:21
09/18/19
09/18
07:21
09/18/19
07:21
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

SU

Suncor

$32.14

-0.31 (-0.96%)

07:21
09/18/19
09/18
07:21
09/18/19
07:21
Conference/Events
Suncor management to meet with Morgan Stanley »

Refinery Tour with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NERV

Minerva

$8.09

-0.03 (-0.37%)

07:20
09/18/19
09/18
07:20
09/18/19
07:20
Initiation
Minerva initiated  »

Minerva initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$138.86

1.25 (0.91%)

07:20
09/18/19
09/18
07:20
09/18/19
07:20
Upgrade
Zimmer Biomet rating change  »

Zimmer Biomet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.